Valeant, Pershing Square get to vote at Allergan shareholder meeting
This article was originally published in Scrip
A federal judge in California has determined that Allergan's largest shareholder Pershing Square Capital Management and Valeant Pharmaceuticals can participate in Allergan's 18 December special shareholder meeting if they comply with certain disclosure requirements; Allergan vowed to file an emergency appeal.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.